Milovanov Iu S, Komiagin Iu V, Shilov E M, Ermolenko V M
Ter Arkh. 1989;61(6):78-81.
The authors are of the opinion that plasmapheresis (PP) combined with immunosuppressant therapy is an effective and a relatively safe method for the treatment of rapidly progressing glomerulonephritis (RPGN). Introduction of PP in multimodality treatment of RPGN made it possible to arrest rapidly progressing renal failure in all 6 treated patients. After PP treatment was over, renal function was recovered completely in 3 patients. One patient manifested the retention of renal failure of medium degree while rare hemodialysis sessions permitted one to control water-electrolyte disorders. In two patients the discontinuation of PP treatment resulted in the progress of renal failure. The data obtained do not make it possible to relate the improvement of renal function exclusively to the action of PP, since all the patients received immunosuppressants. Nevertheless, in 2 cases, the improvement could be attributed to PP, for its discontinuation in these patients (without any changes in the remaining treatment) brought about again the progress of renal failure.
作者认为，血浆置换（PP）联合免疫抑制疗法是治疗快速进展性肾小球肾炎（RPGN）的一种有效且相对安全的方法。在RPGN的多模式治疗中引入PP，使得所有6例接受治疗的患者迅速进展的肾衰竭得以阻止。PP治疗结束后，3例患者的肾功能完全恢复。1例患者表现为中度肾衰竭持续存在，而罕见的血液透析治疗使患者能够控制水电解质紊乱。2例患者停止PP治疗后，肾衰竭病情进展。所获得的数据无法将肾功能的改善完全归因于PP的作用，因为所有患者均接受了免疫抑制剂治疗。然而，在2例患者中，肾功能的改善可归因于PP，因为在这些患者中停止PP治疗（其余治疗无任何变化）再次导致肾衰竭病情进展。
